Attack Surface Reduction Rules not applying or working

You can enable ASR rules using several management tools, depending on your environment. For individual devices, you can ...
The Motley Fool Canada

How a TFSA Can Generate $4,360 in Annual Tax-Free Passive Income

This strategy can boost yield while reducing portfolio risk. Investors can still find decent returns from GICs and TSX dividend stocks. GIC rates are still comfortably above the rate of inflation on ...
FierceBiotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Bloomberg L.P.

Flagship-Backed Generate Bio Seeks $425 Million in US IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...
The Business Journals

Generate:Biomedicines targets $400M IPO amid biotech market thaw

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...
Business Insider

Can OpenAI make the numbers meet? It's a trillion-dollar question.

OpenAI is raising money and considering an IPO amid concerns about its data center spending. Experts say OpenAI plans to spend so much that they worry it will be hard to bring in enough revenue. The ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
FierceBiotech

Flagship-founded antibody biotech Generate is latest to mull IPO

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
The Business Journals

Generate:Biomedicines eyes public markets as AI drug advances to late-stage trials

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
Bloomberg L.P.

Flagship-Backed Drug Firm Generate Biomedicines Files for US IPO

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...
Reuters

Exclusive: Despite new curbs, Elon Musk’s Grok at times produces sexualized images - even when told subjects didn’t consent

NEW YORK, NY, Feb 3 (Reuters) - Elon Musk’s flagship artificial intelligence chatbot, Grok, continues to generate sexualized images of people even when users explicitly warn that the subjects do not ...
The New York Times

Can A.I. Generate New Ideas?

Systems like OpenAI’s GPT-5 are accelerating research in math, biology and chemistry. But there is a debate over whether it can do that work on its own. Credit...Agnes Jonas Supported by By Cade Metz ...